All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE- ABSORB randomised clinical trial

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F20%3A43920763" target="_blank" >RIV/00216208:11120/20:43920763 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064173:_____/20:N0000078

  • Result on the web

    <a href="https://doi.org/10.4244/EIJ-D-19-01079" target="_blank" >https://doi.org/10.4244/EIJ-D-19-01079</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.4244/EIJ-D-19-01079" target="_blank" >10.4244/EIJ-D-19-01079</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE- ABSORB randomised clinical trial

  • Original language description

    Aims: The aim of this study was to investigate clinical outcomes of patients at high risk of restenosis after implantation of a bioresorbable vascular scaffold (BVS). Methods and results: The COMPARE-ABSORB trial was an investigator-initiated, prospective randomised study. Patients at high risk of restenosis were randomly assigned to receive either a BVS or an everolimus-eluting stent (EES). A dedicated implantation technique was recommended for BVS. The primary endpoint was target lesion failure (TLF), defined as the composite of cardiac death, target vessel myocardial infarction (TVMI) or clinically indicated target lesion revascularisation at one year. The enrolment was discontinued prematurely because of a high thrombosis and TVMI rate in the BVS aim. A total of 1,670 patients were recruited (BVS 848 patients and EES 822 patients). TLF occurred in 43 patients (5.1%) of the BVS group and 34 patients (4.2%) of the EES group (absolute difference 0.9%, 95% confidence interval [CI]: -1.2%-3.0%, p non-inferiority &lt;0.001). Definite or probable device thrombosis (2.0% vs 0.6%, hazard ratio [BR] 3.32, 95% CI: 1.22-8.99, p=0.012) and TVMI (4.0% vs 2.1%, HR 1.96, 95% CI: 1.10-3.51, p=0.02) were significantly higher in the BVS group than in the EES group. Conclusions: In patients at high risk of restenosis, non-inferiority of BVS compared with EES in terms of TLF was met at one year. BVS carried a higher risk of device thrombosis and TVMI than EES.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30201 - Cardiac and Cardiovascular systems

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    EuroIntervention

  • ISSN

    1774-024X

  • e-ISSN

  • Volume of the periodical

    16

  • Issue of the periodical within the volume

    8

  • Country of publishing house

    FR - FRANCE

  • Number of pages

    9

  • Pages from-to

    645-653

  • UT code for WoS article

    000582258100003

  • EID of the result in the Scopus database

    2-s2.0-85094684391